Treatments for overactive bladder: focus on pharmacotherapy

Area of Science:

• Urology
• Pharmacology
• Evidence-Based Medicine

Background:

• Overactive bladder syndrome (OAB) is a common condition impacting quality of life.
• Pharmacotherapy, including anticholinergic drugs and vaginal estrogen, is a key treatment modality for OAB.

Purpose of the Study:

• To establish guidelines for the pharmacotherapy of overactive bladder syndrome (OAB).
• To evaluate the safety and efficacy of current OAB pharmacotherapies.
• To guide the selection of anticholinergic therapy based on patient-specific factors.

Main Methods:

• Systematic literature search of Medline and Cochrane Library for anticholinergic drugs and OAB management.
• Inclusion of systematic reviews, randomized controlled trials, and observational studies up to 2010.
• Evidence quality assessment using Canadian Task Force criteria.

Main Results:

• Anticholinergics are the mainstay for OAB pharmacotherapy, with efficacy primarily shown in short-term trials.
• Various oral and transdermal anticholinergics (oxybutynin, tolterodine, trospium, solifenacin, darifenacin) demonstrate objective clinical improvement.
• Vaginal estrogen shows limited efficacy, while botulinum toxin and nerve stimulation are options for refractory cases.

Conclusions:

• Anticholinergic therapy is effective for OAB, but careful patient selection is crucial due to side effects.
• Individual comorbidities should guide the choice of anticholinergic medication.
• Behavioral management and functional electrical stimulation are also recommended primary treatments for OAB.